vs
Medpace Holdings, Inc.（MEDP）与Rithm Capital Corp.（RITM）财务数据对比。点击上方公司名可切换其他公司
Rithm Capital Corp.的季度营收约是Medpace Holdings, Inc.的1.2倍（$828.2M vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs 13.2%，领先5.9%），Rithm Capital Corp.同比增速更快（508.5% vs 32.0%），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -17.9%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
Rithm Capital Corp.是总部位于美国纽约的投资管理机构，核心业务聚焦房地产投资与另类资产投资，依托专业的投研团队和成熟的市场运营经验，为合作伙伴及投资者提供优质的资产配置解决方案与长期收益回报。
MEDP vs RITM — 直观对比
营收规模更大
RITM
是对方的1.2倍
$708.5M
营收增速更快
RITM
高出476.4%
32.0%
净利率更高
MEDP
高出5.9%
13.2%
两年增速更快
MEDP
近两年复合增速
-17.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $828.2M |
| 净利润 | $135.1M | $109.5M |
| 毛利率 | — | — |
| 营业利润率 | 21.6% | 29.9% |
| 净利率 | 19.1% | 13.2% |
| 营收同比 | 32.0% | 508.5% |
| 净利润同比 | 15.5% | 27.7% |
| 每股收益（稀释后） | $4.65 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPRITM
| Q1 26 | — | $828.2M | ||
| Q4 25 | $708.5M | $1.5B | ||
| Q3 25 | $659.9M | $1.1B | ||
| Q2 25 | $603.3M | $1.2B | ||
| Q1 25 | $558.6M | $768.4M | ||
| Q4 24 | $536.6M | $2.1B | ||
| Q3 24 | $533.3M | $619.5M | ||
| Q2 24 | $528.1M | $1.2B |
净利润MEDPRITM
| Q1 26 | — | $109.5M | ||
| Q4 25 | $135.1M | $85.0M | ||
| Q3 25 | $111.1M | $221.5M | ||
| Q2 25 | $90.3M | $311.7M | ||
| Q1 25 | $114.6M | $78.8M | ||
| Q4 24 | $117.0M | $290.2M | ||
| Q3 24 | $96.4M | $121.7M | ||
| Q2 24 | $88.4M | $235.6M |
营业利润率MEDPRITM
| Q1 26 | — | 29.9% | ||
| Q4 25 | 21.6% | 13.8% | ||
| Q3 25 | 21.5% | 21.4% | ||
| Q2 25 | 20.9% | 25.2% | ||
| Q1 25 | 20.3% | 7.4% | ||
| Q4 24 | 23.4% | 23.8% | ||
| Q3 24 | 21.1% | 7.3% | ||
| Q2 24 | 19.9% | 23.6% |
净利率MEDPRITM
| Q1 26 | — | 13.2% | ||
| Q4 25 | 19.1% | 5.7% | ||
| Q3 25 | 16.8% | 20.0% | ||
| Q2 25 | 15.0% | 25.6% | ||
| Q1 25 | 20.5% | 10.3% | ||
| Q4 24 | 21.8% | 14.0% | ||
| Q3 24 | 18.1% | 19.7% | ||
| Q2 24 | 16.7% | 19.2% |
每股收益（稀释后）MEDPRITM
| Q1 26 | — | $0.12 | ||
| Q4 25 | $4.65 | $0.09 | ||
| Q3 25 | $3.86 | $0.35 | ||
| Q2 25 | $3.10 | $0.53 | ||
| Q1 25 | $3.67 | $0.07 | ||
| Q4 24 | $3.67 | $0.50 | ||
| Q3 24 | $3.01 | $0.20 | ||
| Q2 24 | $2.75 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $9.1B |
| 总资产 | $2.0B | $53.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPRITM
| Q1 26 | — | — | ||
| Q4 25 | $497.0M | $1.8B | ||
| Q3 25 | $285.4M | $1.6B | ||
| Q2 25 | $46.3M | $1.6B | ||
| Q1 25 | $441.4M | $1.5B | ||
| Q4 24 | $669.4M | $1.5B | ||
| Q3 24 | $656.9M | $1.6B | ||
| Q2 24 | $510.9M | $1.2B |
总债务MEDPRITM
| Q1 26 | — | — | ||
| Q4 25 | — | $35.4B | ||
| Q3 25 | — | $32.2B | ||
| Q2 25 | — | $31.2B | ||
| Q1 25 | — | $32.2B | ||
| Q4 24 | — | $32.6B | ||
| Q3 24 | — | $29.6B | ||
| Q2 24 | — | $30.1B |
股东权益MEDPRITM
| Q1 26 | — | $9.1B | ||
| Q4 25 | $459.1M | $8.4B | ||
| Q3 25 | $293.6M | $8.5B | ||
| Q2 25 | $172.4M | $7.9B | ||
| Q1 25 | $593.6M | $7.8B | ||
| Q4 24 | $825.5M | $7.8B | ||
| Q3 24 | $881.4M | $7.7B | ||
| Q2 24 | $763.6M | $7.3B |
总资产MEDPRITM
| Q1 26 | — | $53.4B | ||
| Q4 25 | $2.0B | $53.1B | ||
| Q3 25 | $1.8B | $47.2B | ||
| Q2 25 | $1.6B | $44.3B | ||
| Q1 25 | $1.9B | $45.3B | ||
| Q4 24 | $2.1B | $46.0B | ||
| Q3 24 | $2.1B | $42.3B | ||
| Q2 24 | $1.9B | $42.0B |
负债/权益比MEDPRITM
| Q1 26 | — | — | ||
| Q4 25 | — | 4.20× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | — | 3.92× | ||
| Q1 25 | — | 4.14× | ||
| Q4 24 | — | 4.18× | ||
| Q3 24 | — | 3.87× | ||
| Q2 24 | — | 4.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | — |
| 自由现金流经营现金流 - 资本支出 | $188.1M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | — |
8季度趋势，按日历期对齐
经营现金流MEDPRITM
| Q1 26 | — | — | ||
| Q4 25 | $192.7M | $-114.6M | ||
| Q3 25 | $246.2M | $-2.0B | ||
| Q2 25 | $148.5M | $-557.1M | ||
| Q1 25 | $125.8M | $1.4B | ||
| Q4 24 | $190.7M | $-1.8B | ||
| Q3 24 | $149.1M | $768.1M | ||
| Q2 24 | $116.4M | $-55.7M |
自由现金流MEDPRITM
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $183.0M | — | ||
| Q3 24 | $138.5M | — | ||
| Q2 24 | $103.5M | — |
自由现金流率MEDPRITM
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 26.0% | — | ||
| Q2 24 | 19.6% | — |
资本支出强度MEDPRITM
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.4% | — |
现金转化率MEDPRITM
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | -1.35× | ||
| Q3 25 | 2.22× | -9.22× | ||
| Q2 25 | 1.65× | -1.79× | ||
| Q1 25 | 1.10× | 18.03× | ||
| Q4 24 | 1.63× | -6.04× | ||
| Q3 24 | 1.55× | 6.31× | ||
| Q2 24 | 1.32× | -0.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RITM
| Servicing revenue, net | $375.1M | 45% |
| Other | $234.9M | 28% |
| Gain on originated residential mortgage loans, held-for-sale, net | $195.0M | 24% |
| Other revenue | $23.3M | 3% |
